IN2014DN06920A - - Google Patents

Info

Publication number
IN2014DN06920A
IN2014DN06920A IN6920DEN2014A IN2014DN06920A IN 2014DN06920 A IN2014DN06920 A IN 2014DN06920A IN 6920DEN2014 A IN6920DEN2014 A IN 6920DEN2014A IN 2014DN06920 A IN2014DN06920 A IN 2014DN06920A
Authority
IN
India
Prior art keywords
cell
recombinant
coli nissle
directed
ecn
Prior art date
Application number
Inventor
Tobias ÖLSCHLÄGER
Ean Jeong Seo
Jan Wehkamp
Eduard F Stange
Ulrich Sonnenborn
Jürgen Malinka
Hans Proppert
Original Assignee
Pharma Zentrale Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Zentrale Gmbh filed Critical Pharma Zentrale Gmbh
Publication of IN2014DN06920A publication Critical patent/IN2014DN06920A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Abstract

The present invention is directed to a recombinant E. coli Nissle 1917 (EcN) cell transformed with a nucleic acid coding for a defensin protein or a derivative thereof. The invention is further directed to a pharmaceutical composition comprising this cell and a pharmaceutically acceptable carrier as well as a method of producing a recombinant E. coli Nissle 1917 cell and its use in the treatment of Crohn's disease.
IN6920DEN2014 2012-02-17 2013-02-14 IN2014DN06920A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12001091.3A EP2628793A1 (en) 2012-02-17 2012-02-17 Recombinant escherichia coli strains
PCT/EP2013/000446 WO2013120618A1 (en) 2012-02-17 2013-02-14 Recombinant escherichia coli strains

Publications (1)

Publication Number Publication Date
IN2014DN06920A true IN2014DN06920A (en) 2015-04-10

Family

ID=47843228

Family Applications (1)

Application Number Title Priority Date Filing Date
IN6920DEN2014 IN2014DN06920A (en) 2012-02-17 2013-02-14

Country Status (9)

Country Link
US (1) US20160015781A1 (en)
EP (1) EP2628793A1 (en)
CN (1) CN104126003A (en)
AU (1) AU2013220738A1 (en)
CA (1) CA2864870A1 (en)
EA (1) EA201491513A1 (en)
HK (1) HK1199060A1 (en)
IN (1) IN2014DN06920A (en)
WO (1) WO2013120618A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018231834A1 (en) * 2017-06-12 2018-12-20 Duke University Compositions, systems, and methods for the production of biomolecules
US10485632B1 (en) 2018-11-27 2019-11-26 King Saud University Intraoral attachment clip for attachment of objects to edentulous ridges
CN109504643B (en) * 2018-11-27 2022-06-10 扬州大学 Probiotic clone strain integrating four-copy functional F18 pilus operon gene, construction method and application
JP2022539600A (en) * 2019-07-08 2022-09-12 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル Modified ESCHERICHIA COLI strain NISSLE and treatment of gastrointestinal disorders
WO2022067219A1 (en) * 2020-09-28 2022-03-31 The Regents Of The University Of Michigan Methods and compositions for intestinal inflammation
CN115521884B (en) * 2022-07-20 2023-12-29 四川宏展致远环保科技有限公司 Paenibacillus HNP12 and application thereof
CN116496916A (en) * 2022-12-27 2023-07-28 安徽斯拜科生物科技有限公司 Pichia pastoris engineering strain for high yield of HBD-2 and preparation method and application thereof
CN116769814B (en) * 2023-06-16 2024-02-02 苏州泓迅生物科技股份有限公司 Escherichia coli probiotics T7 expression system and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102264905A (en) * 2008-10-30 2011-11-30 基因桥有限责任公司 Method for recombinant expression of polypeptides

Also Published As

Publication number Publication date
AU2013220738A9 (en) 2014-10-16
EP2628793A1 (en) 2013-08-21
WO2013120618A1 (en) 2013-08-22
CN104126003A (en) 2014-10-29
HK1199060A1 (en) 2015-06-19
CA2864870A1 (en) 2013-08-22
EA201491513A1 (en) 2015-01-30
AU2013220738A1 (en) 2014-09-04
US20160015781A1 (en) 2016-01-21

Similar Documents

Publication Publication Date Title
IN2014DN06920A (en)
IN2014DN05670A (en)
MX2019011215A (en) Nucleic acids encoding crispr-associated proteins and uses thereof.
MX2017004592A (en) Pharmaceutical formulations for the oral delivery of peptide or protein drugs.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
TR201900649T4 (en) Mrna therapy for the treatment of ocular diseases.
MX2019000586A (en) Treatment of amd using aav sflt-1.
UA117103C2 (en) Glucagon analogues
SG10201808102WA (en) Bicyclic heterocycle compounds and their uses in therapy
SG10201907775QA (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
MX2013006040A (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis.
MX341324B (en) Polypeptides.
GB2496337A (en) Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
MX2012007806A (en) Pharmaceutical compositions for oral administration of insulin peptides.
NZ703597A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
MD20120127A2 (en) Recombinant Koi herpesvirus (KHV), method for its production and vaccine for the prevention of a disease caused by KHV
MX2014004814A (en) Compounds and methods for enhancing innate immune responses.
MX2015011846A (en) Modified mullerian inhibiting substance (mis) proteins and uses thereof for the treatment of diseases.
EP3747457A3 (en) Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases
PH12015502500B1 (en) Bacteriophage therapy
MX2014004953A (en) Tyrosine based linkers for the releasable connection of peptides.
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
IN2013MU03847A (en)